等待开盘 11-18 09:30:00 美东时间
-1.190
-3.47%
今日重点评级关注:摩根士丹利:维持西部数据"超配"评级,目标价从643美元升至668美元;摩根大通:维持西部数据"超配"评级,目标价从600美元升至650美元
10-26 12:30
Wells Fargo analyst David Lantz maintains Valvoline (NYSE:VVV) with a Overweight and lowers the price target from $45 to $40.
10-23 21:57
今日重点评级关注:HC Wainwright & Co.:维持Alector"买入"评级,目标价从5美元升至8美元;摩根大通:维持ORIC Pharmaceuticals"超配"评级,目标价从23美元升至26美元
10-15 12:36
TD Cowen analyst Max Rakhlenko maintains Valvoline (NYSE:VVV) with a Buy and lowers the price target from $45 to $40.
10-14 23:31
今日重点评级关注:Jones Trading:维持Opus Genetics"买入"评级,目标价从10美元升至17美元;Citizens:维持Rezolute"跑赢大市"评级,目标价从11美元升至15美元
10-07 17:30
今日重点评级关注:Ascendiant Capital:维持NRX Pharmaceuticals"买入"评级,目标价从49美元升至50美元;Ascendiant Capital:维持Atossa Therapeutics"买入"评级,目标价从24美元升至25美元
10-02 08:33
Citigroup analyst Steven Zaccone maintains Valvoline (NYSE:VVV) with a Neutral and lowers the price target from $41 to $34.
10-02 01:47
今日重点评级关注:Ascendiant Capital:维持Outlook Therapeutics"买入"评级,目标价从10美元升至10.5美元;摩根士丹利:维持Aurora Innovation"超配"评级,目标价从14美元升至18美元
09-14 16:05
RBC Capital analyst Steven Shemesh maintains Valvoline (NYSE:VVV) with a Outperform and raises the price target from $46 to $49.
09-11 22:14
今日重点评级关注:康托·菲茨杰拉德:维持Ultragenyx Pharmaceutical"超配"评级,目标价从96美元升至103美元;Canaccord Genuity:维持Ultragenyx Pharmaceutical"买入"评级,目标价从81美元升至83美元
08-21 11:40